Treatment outcomes and cognitive function following electroconvulsive therapy in patients with severe depression

Table 1 Baseline characteristics of the participants

Variable	ECT group (n = 102)	Non-ECT group (n = 102)	P value
Age (yr)	46.3 ± 11.2	45.8 ± 10.9	0.69
Sex (female/male)	58/44	60/42	0.81
Duration of MDD (mo)	24.6 ±12.8	25.4 ± 13.1	0.07
Type of MDD (unipolar/bipolar)	82/20	84/18	0.76
HDRS score	28.4 ± 3.6	28.2 ± 3.7	0.72
WHOQOL-BREF score	42.6 ± 8.9	43.1 ± 9.2	0.66
MoCA score	24.8 ± 3.2	25.1 ± 3.4	0.54
BDNF level (ng/mL)	18.6 ± 5.4	18.9 ± 5.7	0.62
IL-6 level (pg/mL)	3.4 ± 1.2	3.5 ± 1.3	0.58
Cortisol level (ng/mL)	12.7 ± 4.1	12.9 ± 4.3	0.71

Values are shown as average ± deviation or count. ECT: Electroconvulsive treatment; MDD: Major depressive condition; HDRS: Hamilton depression evaluation scale; WHOQOL-BREF: World Health Organization Quality of Life-BREF Assessment; MoCA: Montreal cognitive evaluation; BDNF: Brain-derived neurotrophic factor; IL-6: Interleukin-6.